Natural prevalence of resistance-associated variants in hepatitis C virus NS5A in genotype 3a-infected people who inject drugs in Germany

Journal of Clinical Virology

Volumn 70, Issue , 2015, Pages 43-45

  Walker, Andreas ^a   Siemann, Holger ^b   Groten, Svenja ^c   Ross, R Stefan ^c   Scherbaum, Norbert ^b   Timm, Jörg ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Antiviral treatment; Genotype 3a; Hepatitis C virus; NS5A

Indexed keywords

NONSTRUCTURAL PROTEIN 5A; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ARTICLE; DRUG USE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GERMANY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 3A; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PEOPLE WHO INJECT DRUG; PHYLOGENETIC TREE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; VIRUS LOAD; ANTIVIRAL RESISTANCE; CLASSIFICATION; DNA SEQUENCE; DRUG EFFECTS; FEMALE; GENETIC VARIATION; GENETICS; GENOTYPE; HEALTH SURVEY; HEPACIVIRUS; MALE; VIROLOGY;

DRUG RESISTANCE, VIRAL; DRUG USERS; FEMALE; GENETIC VARIATION; GENOTYPE; GERMANY; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; PHYLOGENY; PREVALENCE; PUBLIC HEALTH SURVEILLANCE; SEQUENCE ANALYSIS, DNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84939626288     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.07.008     Document Type: Article

References (9)

1. Zeuzem S., Dusheiko G.M., Salupere R., Mangia A., Flisiak R., Hyland R.H., Illeperuma A., Svarovskaia E., Brainard D.M., Symonds W.T., Subramanian G.M., McHutchison J.G., Weiland O., Reesink H.W., Ferenci P., Hezode C., Esteban R., Investigators V. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 2014, 370:1993-2001.
2. Christoph Sarrazin, Thomas Berg, Peter Buggisch, Matthias Dollinger, Holger Hinrichsen, Harald Hofer, Dietrich Hüppe, Michael Manns, Stefan Mauss, Jörg Petersen, Karl-Georg Simon, Ingo van Thiel, Heiner Wedemeyer, Zeuzem1 S. 2015. Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C. Addendum zur Hepatitis C Leitlinie.
3. Schink S., Zimmermann R. Virushepatitis C im Jahr 2013. Epidemiologisches Bull. 2014, 2014:275-284.
4. Pybus O.G., Cochrane A., Holmes E.C., Simmonds P. The hepatitis C virus epidemic among injecting drug users. Infect. Genet. Evol.: J. Mol. Epidemiol. Evol. Genet. Infect. Dis. 2005, 5:131-139.
5. Viazov S., Ross S.S., Kyuregyan K.K., Timm J., Neumann-Haefelin C., Isaeva O.V., Popova O.E., Dmitriev P.N., El Sharkawi F., Thimme R., Michailov M.I., Roggendorf M. Hepatitis C virus recombinants are rare even among intravenous drug users. J. Med. Virol. 2010, 82:232-238.
6. Hernandez D., Zhou N., Ueland J., Monikowski A., McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J. Clin. Virol. 2013, 57:13-18.
7. Afdhal N., Reddy K.R., Nelson D.R., Lawitz E., Gordon S.C., Schiff E., Nahass R., Ghalib R., Gitlin N., Herring R., Lalezari J., Younes Z.H., Pockros P.J., Di Bisceglie A.M., Arora S., Subramanian G.M., Zhu Y., Dvory-Sobol H., Yang J.C., Pang P.S., Symonds W.T., McHutchison J.G., Muir A.J., Sulkowski M., Kwo P., Investigators I.O.N. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 2014, 370:1483-1493.
8. Nelson D.R., Cooper J.N., Lalezari J.P., Lawitz E., Pockros P.J., Gitlin N., Freilich B.F., Younes Z.H., Harlan W., Ghalib R., Oguchi G., Thuluvath P.J., Ortiz-Lasanta G., Rabinovitz M., Bernstein D., Bennett M., Hawkins T., Ravendhran N., Sheikh A.M., Varunok P., Kowdley K.V., Hennicken D., McPhee F., Rana K., Hughes E.A., Team A.-S. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015, 61:1127-1135.
9. Kosaka K., Imamura M., Hayes C.N., Abe H., Hiraga N., Yoshimi S., Murakami E., Kawaoka T., Tsuge M., Aikata H., Miki D., Ochi H., Matsui H., Kanai A., Inaba T., Chayama K. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J. Viral hepatitis 2015, 22:158-165.